Continual reassessment method for partial ordering
From MaRDI portal
Recommendations
- Designs for Single- or Multiple-Agent Phase I Trials
- Continual reassessment and related dose-finding designs
- A Curve‐Free Method for Phase I Clinical Trials
- The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
- On the consistency of the continual reassessment method with multiple toxicity constraints
Cites work
- A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents
- A Parallel Phase I/II Clinical Trial Design for Combination Therapies
- Coherence principles in dose-finding studies
- Confidence interval estimation subject to order restrictions
- Continual Reassessment Method: A Likelihood Approach
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Design and Analysis of Phase I Clinical Trials
- Designs for Single- or Multiple-Agent Phase I Trials
- Dose-finding with two agents in phase I oncology trials
- Non-parametric optimal design in dose finding studies
- Two‐Dimensional Dose Finding in Discrete Dose Space
Cited in
(47)- A phase I dose-finding study based on polychotomous toxicity responses
- A Bayesian adaptive design in cancer phase I trials using dose combinations in the presence of a baseline covariate
- A novel framework to estimate multidimensional minimum effective doses using asymmetric posterior gain and \(\epsilon\)-tapering
- Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity
- Adaptive clinical trial designs for phase I cancer studies
- Continual reassessment method for ordered groups
- Designs for Single- or Multiple-Agent Phase I Trials
- A Curve‐Free Method for Phase I Clinical Trials
- On the consistency of the continual reassessment method with multiple toxicity constraints
- Semiparametric Dose Finding Methods for Partially Ordered Drug Combinations
- The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
- Flexible use of copula‐type model for dose‐finding in drug combination clinical trials
- Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information
- Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies
- A simulation-free approach to assessing the performance of the continual reassessment method
- CRM and partial order CRM with adaptive rescaling for dose-finding in immunotherapy trials with a continuous outcome
- A nonparametric Bayesian method for dose finding in drug combinations cancer trials
- Improving safety of the continual reassessment method via a modified allocation rule
- Consistency of the when the curve is not monotone and its application to the POCRM
- Early completion of phase I cancer clinical trials with Bayesian optimal interval design
- Practical implementation of the partial ordering continual reassessment method in a phase I combination-schedule dose-finding trial
- Application of the patient-reported outcomes continual reassessment method to a phase I study of radiotherapy in endometrial cancer
- Bayesian optimization design for finding a maximum tolerated dose combination in phase I clinical trials
- Dual-agent dose-finding in phase I clinical trial -- an extension of rapid enrollment design
- Applying the partial order continual reassessment method to high-dimensional treatment combinations
- A novel method for inserting dose levels mid-trial in early-phase oncology combination studies
- A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies
- A product of independent beta probabilities dose escalation design for dual-agent phase I trials
- Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control
- Accounting for carryover toxicity in phase I clinical trials with intra-patient dose escalation
- Phase I design for completely or partially ordered treatment schedules
- Response to comments on: ``Competing designs for drug combination in phase I dose-finding clinical trials
- Comments on: ``Competing designs for drug combination in phase I dose-finding clinical trials
- Competing designs for drug combination in phase I dose-finding clinical trials
- Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering
- Phase I/II adaptive design for drug combination oncology trials
- A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials
- Dimension of model parameter space and operating characteristics in adaptive dose-finding studies
- A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials
- Escalation with overdose control for phase I drug-combination trials
- Using the time-to-event continual reassessment method in the presence of partial orders
- A design for phase I trials in completely or partially ordered groups
- Performance of toxicity probability interval based designs in contrast to the continual reassessment method
- A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials
- Comparative review of novel model-assisted designs for phase I clinical trials
- On inclusion of covariates in model based dose finding clinical trial designs
- Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach
This page was built for publication: Continual reassessment method for partial ordering
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2893418)
